National
Multiple Sclerosis
Society

ECTRIMS
EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

International Conference on Cell-Based Therapies for Multiple Sclerosis

November 19-21, 2015

Hotel Sofitel Lisbon Liberdade

Lisbon, Portugal



Bélem Tower, Lisbon

Conference Organized Under the Auspices of the

International Advisory Committee on Clinical Trials in Multiple Sclerosis

****

Committee and Conference Support & Funding:

National Multiple Sclerosis Society (US)

National
Multiple Sclerosis
Society

and

European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

ECTRIMS
EUROPEAN COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

****

Additional Conference Support from:

Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

actrims
AMERICAS COMMITTEE FOR TREATMENT
AND RESEARCH IN MULTIPLE SCLEROSIS

and

Multiple Sclerosis International Federation (MSIF)

ms
international
federation

Day/Time	Topic	Sessions/Speakers
Thursday 19 Nov 15	Arrival; 7:00 pm: Welcome dinner – JARDIN ROOM	
Friday 20 Nov 15	**All scientific sessions in LOUVRE ROOM**	
7.00 am	Breakfast available – Hotel restaurant	
	Introduction	
8.00 am	Meeting Purpose/Goals *Why now?* *Meeting structure and rationale for organization*	J. Cohen (US)
8.15 am	Meeting Logistics	S. Reingold (US)
8.20 am	Key note address and overview of topic *What is cell therapy? What themes are common to all cell types? What are most critical areas in each cell type to resolve? Why/how might cell therapy be useful in MS? What are the major approaches?* *How to they differ/how are they similar*	N. Scolding (UK)
8.50 am	Discussion	
	Hematopoietic Stem Cells	SESSION CHAIRS G. Mancardi (IT), A. Bar-Or (CA)
9.00 am	Biology of HSCT: *immunology of immunoablation and reconstitution*	S. Sarantopoulos (US)
9.30 am	Clinical studies in diseases other than MS: an overview; what is the modern concept of the transplant paradigm? Issues of mortality in malignant and non-malignant disease?	M. Pasquini (US)
9.55 am	Discussion	
10.10 am	BREAK -- Louvre Foyer	
10.40 am	Clinical studies in MS to date: *individual studies and a meta-analysis; design, safety and efficacy*	P. Muraro (UK)
11.00 am	Nonmyeloablative hematopoietic stem cell transplantation and disability in MS	R. Burt (US)
11.15 am	The HALT MS trial: 5 year data	R. Nash (US)
11.30 am	Discussion	
11.45 am	Issues related to HSCTs for human use: *conditioning regimens; immunoablation protocols; target populations and efficacy end points and safety*	R. Saccardi (IT)
12.15 pm	Discussion	
12.30 pm	LUNCH	

	Mesenchymal Stem Cells	SESSION CHAIRS: B. Banwell (US), E. Iacobaeus (SE)
1.30 pm	Immunology and neurobiology of MSCs: animal studies relevant to use of MSCs for immune and CNS repair aspects of disease; *MS and other diseases*	R.H. Miller (US)
1.50 pm	Discussion	
2.00 pm	Clinical studies in non-neurologic and neurologic diseases other than MS: *GVD, stroke, IBD, ALS, etc*	S.I Savitz (US)
2.20 pm	Discussion	
2.30 pm	BREAK – LOUVRE FOYER	
3.00 pm	Issues related to MSC cell production: *autologous vs non-disease allogeneic cell source, culture-expansion protocol and cryopreservation vs fresh, etc.*	J. Galipeau (US)
3.20 pm	Discussion	
3.30 pm	Demonstrated and theoretical safety concerns for MSCs: *infusion reactions, ectopic tissue formation, cancer, etc*	O. Ringdén (SE)
3.50 pm	Discussion	
4.00 pm	Clinical studies in MS to date and underway (10 minute "blitz" presentations with 5 minutes discussion focused on technical aspects of trials after each presentation): Phase 1/2 i.v. and i.t. autologous MSCs for MS	
	■ Phase 1/2 i.v. and i.t. autologous MSCs for MS	D. Karussis (IS)
	■ Phase 1/2a i.v. autologous MSC for SPMS	P. Connick (UK)
	■ Phase 1 i.v. autologous culture-expanded MSCs for RRMS, SPMS and PRMS	J.A. Cohen (US)
	■ Phase 1/2 mixed MSC/bone marrow cells for MS	C.M. Rice (UK)
	■ The MESEMS project	A. Uccelli (IT)
	■ Phase 1 trial of intrathecal MSC-neural progenitor cells	S. Sadiq (US)
5.30 pm	General Discussion	
6.00 pm	End of Day 1	
7.30 pm Evening	Group dinner, Casa Museu Medieros e Almeida	

Saturday 20 Nov 15	**All scientific sessions in LOUVRE ROOM**	
7.00 am	Breakfast available – Hotel restaurant	
	Oligo Progenitor Cells and OPC-like Induced Pleuripotent Stem Cells	SESSION CHAIRS: P. Soelberg-Sorensen (DK), P. Calabresi (US)
8.00 am	Biology of remyelination in MS and its animal models	C. ffrench-Constant (UK)
8.20 am	Discussion	
8.30 am	Biology of OPCs and iPSCs *And their use for drug discovery*	P.J. Tesar (US)
8.50 am	Discussion	
9.00 am	Progress report on NY State Consortium study of OPC transplantation in MS: *regulatory issues, human subject concerns and other study initiation; prospects for cell sourcing and production and delivery*	S. Goldman (US/DK)
9.20 am	Discussion	
9.30 am	OPCs as cellular therapeutics: Safety concerns: *mutations, immunogenicity, neoplasia, potential of ectopic tissue formation, etc*	A. Goodman (US)
9.50 am	Discussion	
10.00 am	BREAK -- LOUVRE FOYER	
	Promoting Clinical Trials of Cell Therapy	SESSION CHAIRS: A. Thompson (UK), A. Miller (US)
10.30 am	Creating collaborative networks: the Autoimmune Disease Working Party of the EBMT	D. Farge (FR)
10.50 am	Discussion	
11.00 am	Bridging academic and lab research to human studies and trials: cell sourcing and delivery; cell tracking; outcomes	H. Lazarus (US)
11.20 am	Discussion	
11.30 am	The ethics of human stem cell therapy and issues of patient-funded studies	I. Hyun (US)
11.50 am	Discussion	
12.30 pm	Lunch and breakout sessions – lunch served in 3 separate breakout rooms for 'working lunches"	
	BREAK OUT SESSIONS AND WORKING LUNCHS: <u>Consensus on Design of Future Clinical Trials in MS:</u> o target populations o dose/route/frequency of delivery o efficacy endpoints o safety monitoring o follow-up o building international collaborative studies	

	Group 1: HCST: focus on target population and how to integrate into current DMT treatment paradigms, safety, endpoints, funding – LOUVRE ROOM	Session Leaders: H.P. Hartung (DE), G. Cutter (US)
	Group 2: MSCs: focus on what should be goal of future clinical studies (anti-inflammatory vs reparative) and how to design trials for most important outcomes – JARDIN I ROOM	Session Leaders: D. Miller (UK), M. Freedman (CA)
	Group 3: OPC/iPSC: focus on what we need to do to move these cell types into human trials – JARDIN II ROOM	Session Leaders: A. Green (US), S. Pluchino (UK)
3.00 pm	Reports from Breakout Sessions and discussion on major points of consensus/debate within and across cell types – LOUVRE ROOM	Session Leaders to present results of discussions
4.30 pm	Meeting summary and closure	J. Cohen (US), N. Scolding (UK), M. Pasquini (US)
7.30 pm	Dinner for those staying over – Restaurante Sacramento	

Additional Discussants

H. Atkins (CA)
B. Bebo (US)
J. Bowen (US)
S. Chandran (UK)
G. Comi (IT)
A. Cross (US)
T. Derfuss (CH)
S. Dhib-Jalbut (US)
M. Goldman (US)
L. Griffith (US)
B. Hemmer (DE)
M. Inglese (US)
B. Jubelt (US)
P. Küry (DE)
D. Landsman (US)
C. Laule (CA)
R. Liblau (FR)
R.A. Marrie (CA)
X. Montalban (ES)
E. Mowry (US)
D. Ontaneda (US)
D. Pelletier (US)
L. Perruzzotti-Jametti (UK)
M. Racke (US)
A. Rovira Canellas (SP)
M.P. Sormani (IT)
O. Stüve (US)
M. Trojano (IT)
B. Uitdehaag (NL)
U. Utz (US)
S. Vukusic (FR)
E. Waubant (US
A. Wilkins (UK)